Authera is a pre-clinical-stage biotech company that specializes in the discovery and development of groundbreaking therapeutic biologics. With a strong focus on the study of FcRn biology, we have a profound understanding of the molecular and cellular processes involved in interactions between FcRn and IgG antibodies and albumin. Our unique platform combines cutting-edge biochemical and cellular assays with state-of-the-art in vivo models, enabling us to guide pre-clinical design and selection.

This high-end technology platform has paved the way for our two lead pre-clinical development programs, AuT-1 and AuT-2, which are currently undisclosed. At Authera, we prioritize science-driven collaboration and actively seek partnerships with academia, biotech, and pharmaceutical industries. By partnering with us, you gain access to our expertise in guiding the design and selection of FcRn-binding molecules, ultimately de-risking product development for clinical evaluation.

To stay at the forefront of biotechnology advancements, Authera consistently engages in research collaborations. Recent collaborations with the Jackson Laboratory and argenx have expanded our understanding of FcRn biology. Additionally, we have received funding from the Norwegian Research Council and a grant from Innovation Norway to support our drug development pipeline.

To learn more about Authera and discuss potential collaborations, please reach out to us